leisure time -WSS

leisure time

author：fashion 2025-09-06 08:39:10 - browse：77671

A black and white cutout photo of Feng Zhang on the left of a black and white cutout photo of Alex Aravanis. Both photos are placed on top of yellow geometric shapes and a gradient dark blue background. — Researcher Feng Zhang, left, and Alex Aravanis, the CEO of Moonwalk. Illustration: Christine Kao/STAT; Photo: Katherine Taylor for STAT and Business Wire

A new startup co-founded by CRISPR innovator Feng Zhang, a former executive at Grail and Illumina, and others has raised $57 million to develop a defanged form of gene editing that doesn’t cut the DNA strand.

Moonwalk Therapeutics launched Thursday with funding from Alpha Wave Ventures, ARCH Venture Partners, Future Ventures, Khosla Ventures, GV, and YK Bioventures. It plans to use that money to develop treatments for a variety of diseases, including chronic and aging-related conditions, using what’s called epigenetic editing.

Most of the gene editing technologies being used today slice or nick the DNA strand and make permanent changes to the biological building blocks of genes. Moonwalk, however, plans to alter the activity of genes by focusing on chemical changes. The company is targeting the surrounding chemicals that influence how genes act. This can be done through chemical processes methylation, which turns genes on, or demethylation, which turns genes off.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： Harvard's Jason Buenrostro wins MacArthur grant for genetics work

WSS

How AI can help patients find reliable information about doctors

Will an HIV vaccine ever be a reality?

STAT Summit: How researchers deal with rejection

STAT Readout Newsletter: Biotech news today

2023 Nobel Prize in Medicine goes to Karikó and Weissman

The United States is paying nearly triple for new Covid vaccines

focus

leisure time

leisure time

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

The stability of $0 premiums in Medicare Advantage

Drug repurposing or repositioning? The language matters

2023 Nobel Prize in Medicine goes to Karikó and Weissman

Wildfire smoke exposes gaps in outdoor worker protections

FDA sees ‘potential systemic bias’ in Amgen’s KRAS drug trial

Supreme Court strikes down use of affirmative action

FDA sees ‘potential systemic bias’ in Amgen’s KRAS drug trial

Medical leaders decry Supreme Court decision on affirmative action

WHO recommends second malaria vaccine

explore

Readout Newsletter: Biotech news, Wall Street disappointment, Lilly's drug delays

CRISPR base editing slashes cholesterol levels in monkeys

Smaller biotechs seek to piggyback on weight loss drug boom

Stop Congress from blocking public access to science

IVG is promising — but it won’t replace IVF quite yet

IVG is promising — but it won’t replace IVF quite yet

focus

focus

entertainment

leisure time